NeoGenomics Inc (NEO)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.99B
Last updated: Nov 17, 2026 at 4:26 PM ET
NeoGenomics Inc (NEO) Statistics
NeoGenomics (NEO) has a market cap of $1.99B and an enterprise value of $2.24B. Its trailing P/E is 217.9x.
Total Valuation
Enterprise value is 12.11% above the market cap, as debt exceeds cash.
| Market Cap | $1.99B |
|---|---|
| Enterprise Value | $2.24B |
| Latest price (Nov 17, 2026) | $15.25 |
Key Dates
The next earnings report is expected on Feb 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 28, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.5x and 2.4x. Its year-end P/E ranged from 53.6x to 384.6x from 2016 to 2020.
| P/E Ratio | 217.9x |
|---|---|
| Forward P/E | 74.2x |
| P/S Ratio | 2.5x |
| Forward P/S | 2.5x |
| P/B Ratio | 2.4x |
| P/TBV Ratio | 150.7x |
| P/OCF Ratio | 465.9x |
Enterprise Valuation
Counting debt and cash, the company is valued at 68.2x EBITDA.
| EV / Sales | 2.8x |
|---|---|
| EV / EBITDA | 68.2x |
Price Statistics
The stock is up 47.49% over 52 weeks and trades 12.66% below its 50-day average.
| Beta (1Y) | 1.15 |
|---|---|
| 52-Week Change | +47.49% |
| 1-Month Change | -7.13% |
| 3-Month Change | -8.44% |
| 6-Month Change | +81.76% |
| 5-Year Change | -62.22% |
| 10-Year Change | +115.63% |
| Total Return (1Y) | +47.49% |
| Total Return (3Y CAGR) | -7.72% |
| Total Return (5Y CAGR) | -17.13% |
| Return vs SPY (1Y) | +34.93% |
| Max Drawdown (1Y) | -45.61% |
| Max Drawdown (3Y) | -76.65% |
| Sharpe Ratio (1Y) | 0.72 |
| Correlation with SPY (1Y) | 0.30 |
| 50-Day Average | $17.46 |
| 200-Day Average | $13.02 |
| 52-Week Range | $7.07 to $20.15 |
| RSI (14 Days) | 36.9 |
| Average Volume (20 Days) | 1.75M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.53x current liabilities, and total debt is 0.48x shareholder equity.
| Current Ratio | 3.53x |
|---|---|
| Quick Ratio | 3.31x |
| Debt / Equity | 0.48x |
| Debt / EBITDA | 11.80x |
| Interest Coverage | -10.15x |
Returns and Efficiency
Return on invested capital is -2.49% over the last 12 months, against a 5-year average of -5.58%.
| Return on Equity (ROE) | -4.03% |
|---|---|
| Return on Assets (ROA) | -2.35% |
| Return on Invested Capital (ROIC) | -2.49% |
| Return on Capital Employed (ROCE) | -2.61% |
| ROE (5Y Average) | -9.24% |
| ROA (5Y Average) | -5.34% |
| ROIC (5Y Average) | -5.58% |
| Asset Turnover | 0.57x |
| Inventory Turnover | 16.82x |
| Receivables Turnover | 4.05x |
| Cash Conversion Cycle | 57 days |
Scores
NEO has an Altman Z-Score of 2.33, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 2.33 |
|---|---|
| Altman Z Zone | Grey |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $787.75M over the last 12 months is up 11.08% from the 12 months before.
| Revenue | $787.75M |
|---|---|
| Revenue Growth (YoY) | +11.08% |
| Gross Profit | $345.04M |
| Operating Income | -$47.09M |
| Pretax Income | -$36.18M |
| Net Income | -$32.30M |
| EBITDA | $32.27M |
| EBIT | -$32.93M |
| Reported EPS (TTM) | $0.07 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 58.02% of the $1.38B in total assets.
| Cash and Equivalents | $139.28M |
|---|---|
| Total Debt | $380.69M |
| Net Debt | $241.41M |
| Working Capital | $293.91M |
| Shareholder Equity | $800.64M |
| Tangible Book Value | $13.02M |
| Total Assets | $1.38B |
| Total Liabilities | $576.28M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $32.86M of capital spending, operating cash flow left -$28.58M of free cash flow.
| Operating Cash Flow | $4.28M |
|---|---|
| Capital Expenditures | $32.86M |
| Free Cash Flow | -$28.58M |
| FCF Per Share | -$0.22 |
| Depreciation and Amortization | $65.21M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -5.98%, against a 5-year average of -19.34%.
| Gross Margin | 43.80% |
|---|---|
| Operating Margin | -5.98% |
| Pretax Margin | -4.59% |
| Net Margin | -4.10% |
| EBITDA Margin | 4.10% |
| EBIT Margin | -4.18% |
| FCF Margin | -3.63% |
| Gross Margin (5Y Average) | 39.92% |
| Operating Margin (5Y Average) | -19.34% |
| Net Margin (5Y Average) | -14.33% |
Growth
Revenue grew 12.58% a year over 3 years.
| Revenue Growth (3Y CAGR) | +12.58% |
|---|---|
| Revenue Growth (5Y CAGR) | +10.35% |
Dividends and Yields
NEO does not pay a dividend. Its free cash flow yield is -1.46%.
| Earnings Yield | 0.46% |
|---|---|
| FCF Yield | -1.46% |
| Shareholder Yield | 0.00% |
Peer Position
Against 5 similar companies, NEO has the highest P/E.
P/E RatioPeer median 20.5x
P/S RatioPeer median 3.5x
ROICPeer median -1.31%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +13.33%
| P/E Ratio | 217.9x vs 20.5x median |
|---|---|
| P/S Ratio | 2.5x vs 3.5x median |
| ROIC | -2.49% vs -1.31% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +11.08% vs +13.33% median |
Analyst Forecast
Consensus estimates put revenue growth at 9.01% a year over the next 5 fiscal years.
| Revenue Growth Forecast (5Y CAGR) | +9.01% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NEO
What is NEO's market cap?
NeoGenomics has a market cap of $1.99B. Its enterprise value, which adds debt and subtracts cash, is $2.24B.
What is NEO's P/E ratio?
NeoGenomics has a trailing P/E ratio of 217.9x and a forward P/E of 74.2x.
How many shares of NEO are outstanding?
NeoGenomics has 128.59M shares outstanding. The count is up 0.52% from a year earlier.
Does NEO pay a dividend?
No. NeoGenomics does not pay a dividend.
How much debt does NEO have?
NeoGenomics has $380.69M of total debt and $139.28M of cash and equivalents, a net debt position of $241.41M.
NEO pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts